Despite historical reliance on evidence generated from randomized controlled trials (RCTs), there has been a surge in the number of approvals for cancer therapies based on response rates from single-arm trials. Since treatment-related complications and adverse events can lead to increased mortality among cancer patients, supportive-care decision-making must be based on robust evidence. However, there is a paucity of evidence for supportive oncology and when such evidence does exist, it is rarely translated into practice. Read more here.
(Source: Bishal Gyawali, MD, PhD; Medscape; 10/29/20)